natgillin/translations-raw huggingface dataset:
In a dose escalation study in patients on chronic levodopa therapy treated with 10 mg/day of rasagiline, there were reports of cardiovascular undesirable reactions (including hypertension and postural hypotension) which resolved following treatment discontinuation. 
U ispitivanju postupnog povećavanja doze kod bolesnika na kroničnoj terapiji levodopom liječenih s 10 mg/dan razagilina prijavljene su neželjene kardiovaskularne reakcije (uključujući hipertenziju i posturalnu hipotenziju) koje su se povukle po prestanku liječenja.
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
UVJETI ILI OGRANIČENJA VEZANA UZ SIGURNU I DJELOTVORNU PRIMJENU LIJEKA
Co-administration of rasagiline and ciprofloxacin (an inhibitor of CYP1A2) increased the AUC of rasagiline by 83%. 
Istodobna primjena razagilina i ciprofloksacina (inhibitora CYP1A2) je povećala AUC razagilina za 83%.
Rasagiline clinical trials did not allow concomitant use of fluoxetine or fluvoxamine with rasagiline, but the following antidepressants and doses were allowed in the rasagiline trials: amitriptyline ≤ 50 mg/daily, trazodone ≤ 100 mg/daily, citalopram ≤ 20 mg/daily, sertraline ≤ 100 mg/daily, and paroxetine ≤ 30 mg/daily. 
U kliničkim ispitivanjima razagilina nije bila dozvoljena istodobna upotreba fluoksetina ili fuvoksamina s razagilinom, ali sljedeći antidepresivi i doze bili su dozvoljeni u ispitivanjima razagilina: amitriptilin ≤ 50 mg/dnevno, trazodon ≤ 100 mg/dnevno, citalopram ≤ 20 mg/dnevno, sertralin ≤ 100 mg/dnevno i paroksetin ≤ 30 mg/dnevno.
In post-marketing period, there was one case of elevated blood pressure in a patient using the ophthalmic vasoconstrictor tetrahydrozoline hydrochloride while taking rasagiline. 
U postmarketinškom razdoblju bio je jedan slučaj povišenog krvnog tlaka u bolesnika koji je primijenjivao oftalmički vazokonstriktor tetrahidrozolinklorid tijekom uzimanja razagilina.
Nevertheless, scientific evidence suggests that Parkinson's disease, and not any medicine in particular, is associated with a higher risk of skin cancer (not exclusively melanoma). 
Ipak, znanstveni dokazi upućuju na to da je Parkinsonova bolest, a ne neki lijek posebno, povezana s većim rizikom od karcinoma kože (ne isključivo melanom).
• runny nose (rhinitis) 
• curenje nosa (rinitis)
7 tablets 10 tablets 28 tablets 30 tablets 100 tablets 112 tablets 7 x 1 tablets 10 x 1 tablets 28 x 1 tablets 30 x 1 tablets 100 x 1 tablets 112 x 1 tablets 
7 tableta 10 tableta 28 tableta 30 tableta 100 tableta 112 tableta 7 x 1 tableta 10 x 1 tableta 28 x 1 tableta 30 x 1 tableta 100 x 1 tableta 112 x 1 tableta
Co-administration of rasagiline and theophylline (a substrate of CYP1A2) did not affect the pharmacokinetics of either product. 
Istodobna primjena razagilina i teofilina (supstrata CYP1A2) nije utjecala na farmakokinetiku nijednog od dvaju navedenih lijekova.
Renal impairment: Rasagiline's pharmacokinetics characteristics in subjects with mild (CLcr 50-80 ml/min) and moderate (CLcr 30-49 ml/min) renal impairment were similar to healthy subjects. 
Oštećenje bubrega: Karakteristike farmakokinetike razagilina u osoba s blagim (CLcr 50-80 ml/min) i umjerenim (CLcr 30-49 ml/min) oštećenjem bubrega su slične onima zdravih osoba.
Adverse reactions with at least 2% difference over placebo are marked in italics. 
Nuspojave s najmanje 2% razlike u odnosu na placebo su označene kurzivom.
Other medicines and Rasagiline Mylan 
Drugi lijekovi i Rasagiline Mylan
In the post-marketing period, cases of elevated blood pressure, including rare cases of hypertensive crisis associated with ingestion of unknown amounts of tyramine-rich foods, have been reported in patients taking rasagiline. 
U postmarketinškom razdoblju su prijavljeni slučajevi povišenog krvnog tlaka, uključujući i rijetke slučajeve hipertenzivne krize povezane s ingestijom nepoznatih količina hrane bogate tiraminom u bolesnika koji su uzimali razagilin.
Do not take Rasagiline Mylan: - if you are allergic to rasagiline or any of the other ingredients of this medicine (listed in section 6). 
Nemojte uzimati Rasagiline Mylan: ako ste alergični na razagilin ili bilo koji drugi sastojak ovog lijeka (naveden u dijelu 6.1) ako imate teške probleme s jetrom.
The data collected suggests that Parkinson's disease, and not any medicinal products in particular, is associated with a higher risk of skin cancer (not exclusively melanoma). 
Prikupljeni podaci upućuju na to da je Parkinsonova bolest, a ne neki određeni lijekovi, povezana s većim rizikom od karcinoma kože (ne isključivo melanoma).
In subjects with moderate hepatic impairment, AUC and Cmax were increased by 568% and 83%, respectively (see section 4.4). 
U osoba s umjerenim oštećenjem jetre, AUC se povećava za 568%, a Cmax za 83% (vidjeti dio 4.4).
C/ Castelló no1, Pol. Las Salinas 08830, Sant Boi de Llobregat, Barcelona Spain 
Las Salinas 08830, Sant Boi de Llobregat, Barcelona Španjolska
What you need to know before you take Rasagiline Mylan 3. 
Što morate znati prije nego počnete uzimati Rasagiline Mylan 3.
The difference between the mean change from baseline to week 26/termination (LOCF, Last Observation Carried Forward) was statistically significant (UPDRS, parts I-III: for rasagiline 1 mg compared to placebo -4.2, 95% CI [-5.7, -2.7]; p<0.0001; for rasagiline 2 mg compared to placebo -3.6, 95% CI [-5.0, -2.1]; p<0.0001, UPDRS Motor, part II: for rasagiline 1 mg compared to placebo -2.7, 95% CI [-3.87, -1.55], p<0.0001; for rasagiline 2 mg compared to placebo -1.68, 95% CI [-2.85, -0.51], p=0.0050). 
Last Observation Carried Forward; posljednje provedeno zapažanje preneseno dalje) je bila statistički značajna (UPDRS, dijelovi I-III: za razagilin 1 mg u usporedbi s placebom -4,2, 95% CI [-5,7, -2,7]; p< 0,0001; za razagilin 2 mg u usporedbi s placebom -3,6, 95% CI [-5,0, -2,1]; p< 0,0001, UPDRS motorička, dio II: za razagilin 1 mg u usporedbi s placebom 2,7, 95% CI [-3,87, -1,55], p< 0,0001; za razagilin 2 mg u usporedbi s placebom -1,68, 95% CI [-2,85, -0,51], p=0,0050).
- The other ingredients are microcrystalline cellulose, tartric acid, maize starch, pregelatinized maize starch, talc, stearic acid. 
Drugi sastojci su mikrokristalična celuloza, tartaratna kiselina, kukuruzni škrob, prethodno geliran kukuruzni škrob, talk, stearatna kiselina.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 
DATUM PRVOG ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET/ DATUM OBNOVE ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET
For rasagiline no clinical data on exposed pregnancies is available. 
Nema dostupnih kliničkih podataka o izloženosti razagilinu u trudnoći.
The robustness of the results for the primary efficacy end point, was confirmed in a battery of additional statistical models and was demonstrated in three cohorts (ITT, per protocol and completers). 
Pouzdanost rezultata primarnog ishoda djelotvornosti potvrđena je cijelim skupom dodatnih statističkih modela i pokazana je u tri kohorte (populacija planirana za liječenje (engl. intention to treat, (ITT)), prema protokolu i onim bolesnicima koji su dovršili ispitivanje).
If you are starting treatment with fluoxetine or fluvoxamine, you should wait at least 14 days after stopping Rasagiline Mylan treatment. 
Ako započinjete liječenje fluoksetinom ili fluvoksaminom, morate čekati najmanje 14 dana nakon prekida liječenja lijekom Rasagiline Mylan.
Each tablet contains rasagiline tartrate corresponding to 1 mg rasagiline. 
Svaka tableta sadrži razagilintartarat u količini koja odgovara 1 mg razagilina.
In vitro studies showed that rasagiline at a concentration of 1 μg/ml (equivalent to a level that is 160 times the average Cmax ~ 5.9-8.5 ng/ml in Parkinson's disease patients after 1 mg rasagiline multiple dosing), did not inhibit cytochrome P450 isoenzymes, CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP4A. 
Ispitivanja in vitro su pokazala da razagilin u koncentraciji od 1 µg/ml (istovjetno razini koja je 160 puta veća od prosječne Cmax ~ 5,9-8,5 ng/ml u bolesnika s Parkinsonovom bolešću nakon višekratnog doziranja 1 mg razagilina) nije inhibirao izoenzime citokroma P450, CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2El, CYP3A4 i CYP4A.
Symptoms reported following overdose of rasagiline in doses ranging from 3 mg to 100 mg included dysphoria, hypomania, hypertensive crisis and serotonin syndrome. 
Predoziranje: Simptomi prijavljeni nakon predoziranja razagilinom u dozama u rasponu od 3 mg do 100 mg uključivali su disforiju, hipomaniju, hipertenzivnu krizu i serotoninski sindrom.
For concomitant use of rasagiline with selective serotonin reuptake inhibitors (SSRIs)/selective serotonin-norepinephrine reuptake inhibitors (SNRIs) in clinical trials, see section 4.8. 
Za istodobnu primjenu razagilina sa selektivnim inhibitorima ponovne pohrane serotonina (engl. selective serotonin reuptake inhibitors (SSRI))/selektivnim inhibitorima ponovne pohrane serotonina i noradrenalina (engl. selective serotonin norepinephrine reuptake inhibitors (SNRI)) u kliničkim ispitivanjima, vidjeti dio 4.8.
C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION 
DRUGI UVJETI I ZAHTJEVI ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET
In Parkinson's disease patients receiving chronic levodopa treatment as adjunct therapy, there was no clinically significant effect of levodopa treatment on rasagiline clearance. 
U bolesnika s Parkinsonovom bolešću koji se kronično liječe levodopom kao dodatnom terapijom, nije bilo klinički značajnog učinka liječenja levodopom na klirens razagilina.
If you are starting treatment with Rasagiline Mylan, you should wait at least 5 weeks after stopping fluoxetine treatment. 
Ako započinjete liječenje lijekom Rasagiline Mylan, morate čekati najmanje 5 tjedana nakon prekida liječenja fluoksetinom.
Patients and carers should be made aware of the behavioural symptoms of impulse control disorders that were observed in patients treated with rasagiline, including cases of compulsions, obsessive thoughts, pathological gambling, increased libido, hypersexuality, impulsive behaviour and compulsive spending or buying. 
Bolesnici i skrbnici moraju biti upoznati sa bihevioralnim simptomima poremećaja kontrole impulsa koji su bili primjećeni kod bolesnika liječenih razagilinom, uključujući slučajeve kompulzija, opsesivnih misli, patološkog kockanja, povećanog libida, hiperseksualnosti, impulzivnog ponašanja i kompulzivnog trošenja ili kupovanja.
In the post-marketing period, cases of serotonin syndrome associated with agitation, confusion, rigidity, pyrexia and myoclonus have been reported by patients treated with antidepressants/SNRI concomitantly with rasagiline. 
U postmarketinškom razdoblju su prijavljeni slučajevi serotoninskog sindroma povezanog s agitacijom, konfuzijom, rigidnošću, pireksijom i mioklonusom u bolesnika liječenih antidepresivima/SNRI-em istodobno s razagilinom.
Concomitant administration of rasagiline and entacapone increased rasagiline oral clearance by 28%. 
Istodobna primjena razagilina i entakapona povećava oralni klirens razagilina za 28%.
Rasagiline must not be administered along with other MAO inhibitors (including medicinal and natural products without prescription e.g. St. John's Wort) as there may be a risk of non-selective MAO inhibition that may lead to hypertensive crises (see section 4.3). 
Razagilin se ne smije primjenjivati zajedno s drugim MAO inhibitorima (uključujući lijekove i prirodne preparate bez recepta npr. gospinu travu) jer je moguć rizik od neselektivne MAO inhibicije, koja može dovesti do hipertenzivnih kriza (vidjeti dio 4.3).
Because AUC is not substantially affected, rasagiline can be administered with or without food. 
Budući da se AUC bitno ne mijenja, razagilin se može primijeniti s hranom ili bez nje.
• heart attack (myocardial infarction) 
• srčani udar (infarkt miokarda)
In the double blind placebo-controlled studies, 529 patients were treated with rasagiline 1 mg/day for 212 patient years and 539 patients received placebo for 213 patient years. 
U dvostruko slijepim placebo kontroliranim ispitivanjima 529 bolesnika bilo je liječeno razagilinom 1 mg/dan kroz 212 bolesničkih godina, a 539 bolesnika je primalo placebo kroz 213 bolesničkih godina.
In post-marketing experience, these symptoms have also been observed in Parkinson's disease patients treated with rasagiline. 
U postmarketinškom iskustvu ovi su simptomi također opaženi u bolesnika s Parkinsonovom bolešću liječenih razagilinom.
White to off-white, oblong (approximately 11.5 mm x 6 mm) biconvex tablets, debossed with ‘R9SE' on one side and ‘1' on the other side. 
Bijele do bjelkaste, duguljaste (približne veličine 11,5 mm x 6 mm) bikonveksne tablete s utisnutom oznakom «R9SE» na jednoj strani i «1» na drugoj strani.
Therefore, in view of the MAO inhibitory activity of rasagiline, the concomitant administration of rasagiline and dextromethorphan is not recommended (see section 4.4). 
Stoga se, s obzirom na MAO inhibitornu aktivnost razagilina, ne preporučuje istodobna primjena razagilina i dekstrometorfana (vidjeti dio 4.4).
In vitro metabolism studies have indicated that cytochrome P450 1A2 (CYP1A2) is the major enzyme responsible for the metabolism of rasagiline. 
Ispitivanja metabolizma in vitro su uputila na to da je citokrom P450 1A2 (CYP1A2) glavni enzim odgovoran za metabolizam razagilina.
It is not known whether rasagiline is excreted in human milk. 
Nije poznato izlučuje li se razagilin u majčino mlijeko.
• irritation of the skin (dermatitis) 
• nadražaj kože (dermatitis)
Serious adverse reactions have been reported with the concomitant use of pethidine and MAO inhibitors including another selective MAO-B inhibitor. 
Prijavljene su ozbiljne nuspojave pri istodobnoj primjeni petidina i MAO inhibitora, uključujući i drugi selektivni MAO-B inhibitor.
There is a risk that the plasma levels of rasagiline in smoking patients could be decreased, due to induction of the metabolising enzyme CYP1A2. 
Kod bolesnika koji su pušači postoji rizik od smanjenja razina razagilina u plazmi zbog indukcije metabolizirajućeg enzima CYP1A2.
Common: depression (5.4% vs. 2%), hallucinations (1.3% vs. 0.7%) Nervous system disorders 
Često: depresija (5,4% naspram 2%), halucinacije (1,3% naspram 0,7%) Poremećaji živčanog sustava
The mean total daily decrease in the OFF time was similar in the entacapone group (-0.80h, 95% CI [-1.20, -0.41], p<0.0001) to that observed in the rasagiline 1 mg group. 
Srednje ukupno dnevno smanjenje u OFF vremenu u entakapon skupini (-0,80 h, 95% CI [-1,20, -0,41], p<0,0001) bilo je slično onom opaženom u razagilin 1 mg skupini.
In this study, the primary measure of efficacy was the change from baseline in the total score of the Unified Parkinson's Disease Rating Scale (UPDRS, parts I-III). 
U ovom ispitivanju je primarna mjera djelotvornosti bila promjena od početne vrijednosti u ukupnom zbroju ujedinjene ljestvice za ocjenu Parkinsonove bolesti (engl.
The list below includes adverse reactions which were reported with a higher incidence in placebo controlled studies in patients receiving 1 mg/day rasagiline (rasagiline group n=380, placebo group n=388). 
Niže navedeni popis uključuje nuspojave koje su bile prijavljene s većom incidencijom u placebo kontroliranim ispitivanjima u bolesnika koji su primali 1 mg/dan razagilina (razagilin skupina n=380, placebo skupina n=388).
Common: dermatitis (2.0% vs. 0%) 
Često: dermatitis (2,0% naspram 0%)
Renal impairment No change in dose is required for renal impairment. 
Kod oštećenja bubrega nije potrebna promjena doze.
What Rasagiline Mylan looks like and contents of the pack Rasagiline tablets are presented as white to off-white, oblong (approximately 11.5 mm x 6 mm) biconvex tablets, debossed with ‘R9SE' on one side and ‘1' on the other side. 
Kako Rasagiline Mylan izgleda i sadržaj pakiranja Rasagiline tablete su bijele do bjelkaste, duguljaste (približne veličine 11,5 mm x 6 mm) bikonveksne tablete s utisnutom oznakom “R9SE” na jednoj strani i “1” na drugoj strani.
Very common: dyskinesia (10.5% vs. 6.2%) 
Vrlo često: diskinezija (10,5% naspram 6,2%)
Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated-dose toxicity and reproduction toxicity. 
Neklinički podaci na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza i reproduktivne toksičnosti ne ukazuju na poseban rizik za ljude.
Rasagiline Mylan may be taken with or without food. 
Rasagiline Mylan se može uzeti sa ili bez hrane.
• stroke (cerebrovascular accident) 
• moždani udar (cerebrovaskularni događaj)
Hepatic impairment: In subjects with mild hepatic impairment, AUC and Cmax were increased by 80% and 38%, respectively. 
Oštećenje jetre: U osoba s blagim oštećenjem jetre, AUC se povećava za 80%, a Cmax za 38%.
What you need to know before you take Rasagiline Mylan 
Što morate znati prije nego počnete uzimati Rasagiline Mylan
In patients taking Rasagiline Mylan and/or other medications used to treat Parkinson's disease, behaviours such as compulsions, obsessive thoughts, addictive gambling, excessive spending, impulsive behaviour and an abnormally high sex drive or an increase in sexual thoughts or feelings have been observed. 
Kod bolesnika koji uzimaju Rasagiline Mylan i/ili druge lijekove koji se koriste za liječenje Parkinsonove bolesti bila su opažena ponašanja kao što su kompulzije, opsesivne misli, ovisnost o kockanju, prekomjerno trošenje, impulzivno ponašanje i nenormalno visok seksualni nagon ili povećanje misli i osjećanja povezanih sa seksualnošću.
• musculoskeletal pain 
• mišićno-koštana bol
Mylan, Lda. 
Portugal Mylan Lda.
In study III, the mean difference compared to placebo was -0.94h, 95% CI [-1.36, -0.51], p<0.0001. 
U ispitivanju III srednja razlika u usporedbi s placebom je iznosila 0,94 h, 95% CI [-1,36, -0,51], p< 0,0001.
There have been reports of medicinal product interactions with the concomitant use of dextromethorphan and non-selective MAO inhibitors. 
Prijavljene su interakcije lijekova pri istodobnoj primjeni dekstrometorfana i neselektivnih MAO inhibitora.
The list below includes adverse reactions which were reported with a higher incidence in placebo controlled studies, in patients receiving 1 mg/day rasagiline (rasagiline group n=149, placebo group n=151). 
Niže navedeni popis uključuje nuspojave koje su bile prijavljene s većom incidencijom u placebo kontroliranim ispitivanjima, kod bolesnika koji su primali 1 mg/dan razagilina (razagilin skupina n=149, placebo skupina n=151).
Conjugation of rasagiline and its metabolites was also found to be a major elimination pathway to yield glucuronides. 
Također je otkriveno da je glavni eliminacijski put konjugacija razagilina i njegovih metabolita do stvaranja glukuronida.
597 678 01 Blansko Czech Republic 
Synthon s.r.o Brněnská 32/čp. 597 678 01 Blansko Češka Republika
In vitro experiments indicate that both routes of rasagiline metabolism are dependent on cytochrome P450 system, with CYP1A2 being the major iso-enzyme involved in rasagiline metabolism. 
Pokusi in vitro indiciraju na to da su oba puta metabolizma razagilina ovisna o sustavu citokroma P450, s CYP1A2 kao glavnim izoenzimom uključenim u metabolizam razagilina.
In study II, the mean difference in the number of hours spent in the “OFF” state compared to placebo was -0.78h, 95% CI [-1.18, -0.39], p=0.0001. 
U ispitivanju II, srednja razlika u broju sati provedenih u „OFF“ stanju u usporedbi s placebom je iznosila -0,78 h, 95% CI [-1,18, -0,39], p=0,0001.
With MAO inhibitors there have been reports of medicinal product interactions with the concomitant use of sympathomimetic medicinal products. 
Kod MAO inhibitora su prijavljene interakcije lijekova pri istodobnoj primjeni simpatomimetskih lijekova.
Certain antidepressants (selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, tricyclic or tetracyclic antidepressants) the antibiotic ciprofloxacin used against infections the cough suppressant dextromethorphan sympathomimetics such as those present in eye drops, nasal and oral decongestants and cold medicine containing ephedrine or pseudoephedrine 
Posavjetujte se s liječnikom prije uzimanja bilo kojeg od sljedećih lijekova zajedno s lijekom Rasagiline Mylan: određenih antidepresiva (selektivnih inhibitora ponovne pohrane serotonina, selektivnih inhibitora ponovne pohrane serotonina i noradrenalina, tricikličkih ili tetracikličkih antidepresiva) antibiotika ciprofloksacina koji se upotrebljava protiv infekcija dekstrometorfana koji se primjenjuje protiv kašlja simpatomimetika poput onih sadržanih u kapima za oči, nazalnim i oralnim dekongestivima i lijekovima za prehladu koji sadrže efedrin ili pseudoefedrin.
You must wait at least 14 days after stopping Rasagiline Mylan treatment and starting treatment with MAO inhibitors or pethidine. 
Morate čekati najmanje 14 dana nakon prestanka liječenja lijekom Rasagiline Mylan i početka liječenja MAO inhibitorima ili petidinom.
Severe hepatic impairment. 
Teško oštećenje jetre.
If you forget to take Rasagiline Mylan 
Ako ste zaboravili uzeti Rasagiline Mylan
Caution should be used when initiating treatment with rasagiline in patients with mild hepatic impairment. 
Oprez je nužan na početku liječenja razagilinom u bolesnika s blagim oštećenjem jetre.
In parentheses is the adverse reaction incidence (% of patients) in rasagiline vs. placebo, respectively. 
U zagradama je navedena incidencija nuspojava (% bolesnika) kod razagilina naspram placebu.
Synthon Hispania S.L., C/ Castelló no1, Pol. Las Salinas, 08830, Sant Boi de Llobregat, Barcelona, Spain 
Las Salinas, 08830, Sant Boi de Llobregat, Barcelona, Španjolska
Uncommon: decreased appetite (0.7% vs. 0%) Psychiatric disorders 
Manje često: smanjen apetit (0,7% naspram 0%) Psihijatrijski poremećaji
Common: dystonia (2.4% vs. 0.8%), carpal tunnel syndrome (1.3% vs. 0%), balance disorder (1.6% vs. 0.3%) 
Često: distonija (2,4% naspram 0,8%), sindrom karpalnog tunela (1,3% naspram 0%), poremećaj ravnoteže (1,6% naspram 0,3%)
• abnormal movements (dyskinesia) 
• abnormalni pokreti (diskinezija)
Rasagiline pharmacokinetics are linear with dose over the range of 0.5-2 mg. Its terminal half-life is 0.6-2 hours. 
Farmakokinetika razagilina je linearna s dozama u rasponu od 0,5-2 mg.
In study III, patients were randomly assigned to receive placebo (159 patients), rasagiline 0.5 mg/day (164 patients), or rasagiline 1 mg/day (149 patients), and were treated for 26 weeks. 
U ispitivanju III, bolesnici su metodom slučajnog odabira bili raspodijeljeni da prime placebo (159 bolesnika), razagilin 0,5 mg/dan (164 bolesnika) ili razagilin 1 mg/dan (149 bolesnika) i bili su liječeni 26 tjedana.
Rasagiline Mylan 1 mg tablets rasagiline 
Rasagiline Mylan 1 mg tablete razagilin
The concomitant use of rasagiline and dextromethorphan or sympathomimetics such as those present in nasal and oral decongestants or cold medicinal product containing ephedrine or pseudoephedrine is not recommended (see section 4.5). 
Ne preporučuje se istodobna primjena razagilina i dekstrometorfana ili simpatomimetika poput onih sadržanih u nazalnim i oralnim dekongestivima ili lijekova za prehladu koji sadrže efedrin ili pseudoefedrin (vidjeti dio 4.5).
The concomitant use of rasagiline and fluoxetine or fluvoxamine should be avoided (see section 4.5). 
Istodobnu primjenu razagilina i fluoksetina ili fluvoksamina potrebno je izbjegavati (vidjeti dio 4.5).
Concomitant treatment with other monoamine oxidase (MAO) inhibitors (including medicinal and natural products without prescription e.g. St. John's Wort) or pethidine (see section 4.5). 
Istodobno liječenje drugim inhibitorima monoaminooksidaze (MAO) (uključujući lijekove bez recepta i prirodne preparate npr. gospinu travu) ili petidinom (vidjeti dio 4.5).
Common: hallucinations (2.9% vs. 2.1%), abnormal dreams (2.1% vs. 0.8%) Uncommon: confusion (0.8% vs. 0.5%) 
Često: halucinacije (2,9% naspram 2,1%), abnormalni snovi (2,1% naspram 0,8%) Manje često: konfuzija (0,8% naspram 0,5%) Poremećaji živčanog sustava